COVID-19: EMA Says Guillain-Barré Syndrome Is A Side-Effect Of AZ’s Vaxzevria

But EU Safety Assessment Body Rules Out Link with Menstrual Disorders

The EU’s pharmacovigilance committee has recommended safety updates for two COVID-19 vaccines, and is keeping its eye on a range of possible side-effects with all four authorized products.

corona vaccines
The EMA gives regular safety updates on COVID-19 vaccines • Source: Shutterstock

The European Medicines Agency says that Guillain-Barré syndrome should be added as a side-effect in the EU product information for AstraZeneca PLC/Oxford University’s COVID-19 vaccine Vaxzevria, and that adverse events such as lymphadenopathy, tinnitus, diarrhea and vomiting should be listed for the Janssen Pharmaceutical Cos. vaccine.

There are no new safety updates for the other two vaccines approved in the EU – Pfizer Inc./BioNTech...

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography